Neprilysin
Neutral endopeptidase; NEP; Cluster of differentiation 10; CD10

Neprilysin (NEP) is a type II membrane metalloendopeptidase composed of 750 residues with an active site containing a zinc-binding motif (HEXXH) at the extracellular carboxyl terminal domain. Neprilysin is capable of degrading the monomeric and the oligomeric forms of Aβ peptide. Neprilysin is the dominant Aβ peptide-degrading enzyme in the brain; Neprilysin becomes inactivated and down-regulated during both the early stages of Alzheimer's disease (AD) and aging.

Neprilysin is a neutral endopeptidase and its inhibition increases bioavailability of natriuretic peptides, bradykinin, and substance P, resulting in natriuretic, vasodilatory, and anti-proliferative effects.
Neprilysin Inhibitors

Candoxatril
(UK 79300)
Cat. No.: HY-19649
Candoxatril is a neutral endopeptidase (NEP) inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

NEP-In-1
Cat. No.: HY-U00294
NEP-In-1 is a neutral endopeptidase (NEP) inhibitor with IC_{50} of 2 nM for dNEP.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Phosphoramidon Disodium
Cat. No.: HY-N2021A
Phosphoramidon disodium is a metalloprotease inhibitor. Phosphoramidon inhibits endothelin-converting enzyme (ECE), neutral endopeptidase (NEP), and angiotensin-converting enzyme (ACE) with IC_{50} values of 3.5, 0.034, and 78 μM, respectively.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Sacubitril
(AHU-377)
Cat. No.: HY-15407
Sacubitril (AHU-377) is a potent NEP inhibitor with an IC_{50} of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.

Purity: 99.71%
Clinical Data: Phase 4
Size: 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sacubitril hemicalcium salt
(AHU-377 (hemicalcium salt))
Cat. No.: HY-15407A
Sacubitril hemicalcium salt (AHU-377 hemicalcium salt) is a potent NEP inhibitor with an IC_{50} of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.

Purity: 99.64%
Clinical Data: Phase 4
Size: 10 mM x 1 mL, 5 mg, 10 mg, 20 mg, 50 mg, 100 mg, 500 mg, 1 g

Racecadotril
(Acetorphan)
Cat. No.: HY-17399
Racecadotril (acetorphan), a potent enkephalinase inhibitor (IC_{50}= 4.5 μM), protects endogenous enkephalins from degradation. IC_{50} value: 4.5 μM
Target: Enkephalinase
Racecadotril is a peripherally acting enkephalinase inhibitor with an IC_{50} of 4.5 μM.

Purity: >98.0%
Clinical Data: Launched
Size: 10 mM x 1 mL, 200 mg, 1 g

SQ28603
(SQ28,603; Squibb 28603)
Cat. No.: HY-U00171
SQ28603 is a potent and selective inhibitor of neutral endopeptidase 3.4.24.11 (NEP), an enzyme that degrades atrial natriuretic peptide (ANP).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg
TD-0212 (compound 35) is an orally active dual pharmacology angiotensin II type 1 receptor (AT\(_1\)) antagonist and nephrilysin (NEP) inhibitor, with a pK\(_i\) of 8.9 for AT\(_1\) and a pIC\(_{50}\) of 9.2 for NEP.

| Purity:     | >98%        |
| Clinical Data: | No Development Reported |
| Size:       | 100 mg, 250 mg, 500 mg |

www.MedChemExpress.com